All In Biotech

Drug Trial Radar · NCT00455195

Late-Onset Treatment Study Extension Protocol

An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704

Last checked: Nov 20, 2026Latest source record: Mar 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

81

Actual

Start

Mar 2007

Primary completion

Oct 2008

Study completion Nov 2008

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Apr 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Pompe disease (also known as glycogen storage disease Type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The objective of this extension study is to assess the long-term safety and efficacy of alglucosidase alfa treatment in patients with Late-Onset Pompe Disease who were previously treated under the placebo-controlled, double-blind study AGLU02704 (NCT00158600).

Conditions

  • Pompe Disease (Late-Onset)
  • Glycogen Storage Disease Type II (GSD-II)
  • Glycogenesis Type II
  • Acid Maltase Deficiency (AMD)

Interventions

  • alglucosidase alfaBiological

    IV infusion of 20 mg/kg; every other week (qow)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Summary of Participants Reporting Treatment-Emergent Adverse Events For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0 to 2.5 years
  2. Baseline Values (Week 0) of Functional Endurance as Measured by Six-Minute Walk Test (6MWT) For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0
  3. Change From Baseline (Week 0) in the Six-Minute Walk Test (6MWT) at Week 104 For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0, Week 104
  4. Baseline Values (Week 0) for Percent Predicted Forced Vital Capacity (FVC) For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0
  5. Change From Baseline (Week 0) in the Percent Predicted Forced Vital Capacity (FVC) at Week 104 For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600)Time frame: Week 0, Week 104

Locations

31 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Anchorage, Alaska

  • Site not named

    Phoenix, Arizona

  • Site not named

    Beverly Hills, California

  • Site not named

    San Diego, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Coral Springs, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Kansas City, Kansas

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Omaha, Nebraska

  • Site not named

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Toledo, Ohio

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Greenville, South Carolina

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Seattle, Washington

  • Site not named

    Green Bay, Wisconsin

  • Site not named

    Westmead, Australia

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Sherbrooke, Quebec, Canada

  • Site not named

    Paris, France

  • Site not named

    Rotterdam, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.